Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections

By P. Moise-Broder, Alan Forrest, M. Birmingham, Jerome J. Schentag. Clinical Pharmacokinetics, 2004

755 citations recorded by the source corpus.

Subfields: Applied Microbiology and Biotechnology, Infectious Diseases, Pharmacology

View Paper: https://www.semanticscholar.org/paper/295108b4dfcb629b335c4d7127e1d2a1d7938136

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Applied Microbiology and Biotechnology

1. S. Cosgrove

In Infectious Diseases

1. D. Levine
2. Robert S. Daum
3. S. Cosgrove
4. B. Lomaestro
5. J. Rotschafer
6. Henry F. Chambers

In Pharmacology

1. B. Lomaestro
2. J. Rotschafer
3. D. Levine

Citations in the corpus

• High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. (2006, background): “Duration of vancomycin therapy, mean (range), d 17 (13-54) 11 (6-15) .”
• Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. (2011, background): “was associated with improved clinical response and microbiologic eradication [307].”
• Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 (2017, background): “Similarly, inadequate early vancomycin trough plasma concentrations (in relation to pathogen minimum inhibitory concentration [MIC]) have been associated with clinical failure for serious MRSA infections [130] (including nosocomial pneumonia [131] and septic shock [132].”
• The pharmacokinetic and pharmacodynamic properties of vancomycin. (2006, background): “[26] examined the relationship between the vancomycin AUC/MIC and the outcomes of 108 patients with methicillin-resistant S.”
• Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. (2008, background): “[23] examined the relationship between the vancomycin AUC/MIC and outcome for 63 patients with lower respiratory tract infection due to S.”
• Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications (2010, background): “The probabilities of achieving this target with an isolate with an MIC of 1 g per ml with serum vancomycin trough levels of 10 and 15 g per ml were 40 and 60%, respectively (210).”
• Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Socie (2020, background): “More recent clinical assessments that identified a link between AUC/MIC ratio and outcomes also assessed the AUC values achieved early in the course of therapy.(1,3,5-7,10,13,20-22) The 2009 vancomycin guideline stated that the trough should be assessed prior to steady-state conditions (ie, prior to”